Ethinylestradiol/drospirenone

From WikiProjectMed
Jump to navigation Jump to search
Ethinylestradiol/drospirenone
Ethinylestradiol.svg
Ethinylestradiol
Drospirenone.svg
Drospirenone
Combination of
EthinylestradiolEstrogen
DrospirenoneProgestogen; Progestin; Antimineralocorticoid; Antiandrogen
Names
Trade namesWith 30 μg ethinylestradiol: Yasmin, others
With 20 μg ethinylestradiol: Yaz, Yasminelle, others
Other namesEE/DRSP
Clinical data
Drug classEstrogen; Progestin; Progestogen; Antimineralocorticoid; Antiandrogen
Pregnancy
category
  • AU: B3[1]
  • US: N (Not classified yet)[1]
Routes of
use
By mouth
External links
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa601050
Legal
License data
Legal status

Ethinylestradiol/drospirenone (EE/DRSP), sold under the brand name Yasmin among others, is a combination of ethinylestradiol (EE), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used as a birth control pill to prevent pregnancy in women.[2][3][4][5] It is also indicated for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea (painful menstruation) in women.[3] The medication is taken by mouth and contains 30 μg EE and 3 mg DRSP per tablet (brand names Yasmin, others) or 20 μg EE and 3 mg DRSP per tablet (brand names Yaz, Yasminelle, Nikki, others).[4][5] A formulation with levomefolic acid (vitamin B9) has also been marketed (brand names Beyaz, Safyral, others), with similar indications.[6][7] EE/DRSP is marketed widely throughout the world.[8]In 2017, it was the 98th most commonly prescribed medication in the United States, with more than eight million prescriptions.[9][10]

Society and culture

Cost

In 2017, it was the 98th most commonly prescribed medication in the United States, with more than eight million prescriptions.[9][10]

See also

References

  1. 1.0 1.1 "Drospirenone / estradiol (Angeliq) Use During Pregnancy". Drugs.com. 6 September 2018. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
  2. "Archive copy". Archived from the original on 2021-08-28. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
  3. 3.0 3.1 "Archive copy". Archived from the original on 2019-12-23. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
  4. 4.0 4.1 "Archive copy" (PDF). Archived (PDF) from the original on 2021-04-02. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
  5. 5.0 5.1 "Yaz" (PDF). Archived from the original (PDF) on October 31, 2017. Retrieved October 31, 2017.
  6. "Archive copy". Archived from the original on 2019-12-23. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
  7. "Archive copy" (PDF). Archived (PDF) from the original on 2021-03-30. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
  8. "Archive copy". Archived from the original on 2020-11-29. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
  9. 9.0 9.1 "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  10. 10.0 10.1 "Drospirenone; Ethinyl Estradiol - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.

External links

Identifiers: